Loading...
•
Mar 31, 2023
DBV Technologies Q1 2023 Earnings Report
DBV Technologies reported financial results for Q1 2023.
Key Takeaways
DBV Technologies reported a net loss of $20.5 million for Q1 2023, with cash and cash equivalents of $192.3 million. The company's operating expenses increased due to the initiation of the VITESSE trial.
Cash and cash equivalents totaled $192.3 million at the end of Q1 2023.
Net loss for the quarter was $20.5 million.
Operating expenses increased to $23.3 million, driven by research and development expenses.
Initiation of the VITESSE trial impacted cash used for operations.
DBV Technologies
DBV Technologies
Forward Guidance
This press release contains forward-looking statements and estimates, including statements regarding DBV’s financial condition and planned clinical efforts. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties.